Blood Cancer - HealthQuill

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

by HealthQuill
October 9, 2025
0 Comments

A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.

Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

by HealthQuill
June 4, 2025
0 Comments

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.

Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

by HealthQuill
November 9, 2024
0 Comments

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.

Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

by HealthQuill
October 3, 2024
0 Comments

The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.

Drugs Health Pharma

US drug regulator blocks Regeneron’s blood cancer therapy

The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.

by HealthQuill
August 21, 2024
0 Comments

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.

Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.

by HealthQuill
August 9, 2024
0 Comments

The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.

Drugs Health Pharma

USFDA gives nod to Janssen Research’s blood cancer therapy

The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.

by HealthQuill
August 1, 2024
0 Comments

Drugs Health Medical

Strategy of genetic shielding of blood cells helps eradicate blood cancer

HQ Team July 18, 2024: In a reversal strategy in the war against cancer, researchers are now aiming to genetically cloak healthy cells.

by HealthQuill
July 17, 2024
0 Comments

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to a statement.

Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.